PULMONX CORPORATION (LUNG) Spending and interest coverage
- R&D / revenue · 12 months: Value 22.14%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 19.72%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 22.14% | Research and development expense / revenue. Period ending 2026-06-30. $19.36M ÷ $87.44M × 100 ≈ 22.14% |
| Stock-based compensation / revenue · 12 months | 19.72% | Share-based compensation / revenue. Period ending 2026-06-30. $17.24M ÷ $87.44M × 100 ≈ 19.72% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 19.36M USD | Research and Development Expense |
| Revenue | 87.44M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 17.24M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -46.31M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $19.36M | $87.44M | $17.24M | $-46.31M | (m) | 22.14% | 19.72% | (m) | (m) |
| 2026-03-31 | $19.63M | $88.55M | $19.76M | $-52.06M | (m) | 22.17% | 22.31% | (m) | (m) |
| 2025-12-31 | $19.49M | $90.50M | $21.23M | $-53.66M | (m) | 21.54% | 23.46% | (m) | (m) |
| 2025-09-30 | $18.91M | $91.66M | $22.52M | $-57.18M | (m) | 20.63% | 24.56% | (m) | (m) |
| 2025-06-30 | $17.81M | $90.55M | $23.19M | $-56.91M | (m) | 19.67% | 25.61% | (m) | (m) |
| 2025-03-31 | $18.12M | $87.47M | $22.89M | $-57.73M | (m) | 20.71% | 26.17% | (m) | (m) |
| 2024-12-31 | $17.57M | $83.79M | $22.95M | $-57.70M | (m) | 20.97% | 27.40% | (m) | (m) |
| 2024-09-30 | $17.46M | $79.30M | $23.03M | $-58.21M | (m) | 22.02% | 29.04% | (m) | (m) |
| 2024-06-30 | $17.94M | $76.58M | $23.19M | $-59.25M | (m) | 23.43% | 30.29% | (m) | (m) |
| 2024-03-31 | $18.04M | $72.99M | $23.14M | $-60.07M | $3.54M | 24.71% | 31.70% | -16.95× | Reported |
| 2023-12-31 | $18.08M | $68.67M | $22.10M | $-61.94M | $3.23M | 26.33% | 32.18% | -19.16× | Reported |
| 2023-09-30 | $18.09M | $64.82M | $20.75M | $-62.64M | $2.69M | 27.90% | 32.01% | -23.32× | Reported |
| 2023-06-30 | $18.23M | $60.66M | $19.05M | $-61.40M | $2.08M | 30.06% | 31.40% | -29.52× | Reported |
| 2023-03-31 | $16.12M | $57.41M | $17.57M | $-59.37M | $1.44M | 28.07% | 30.60% | -41.26× | Reported |
| 2022-12-31 | $15.40M | $53.66M | $16.45M | $-58.64M | $1.07M | 28.69% | 30.65% | -55.01× | Reported |
| 2022-09-30 | $15.20M | $51.95M | $15.21M | $-56.38M | $906.00K | 29.27% | 29.28% | -62.23× | Reported |
| 2022-06-30 | $13.65M | $51.70M | $13.85M | $-52.21M | $827.00K | 26.40% | 26.78% | -63.13× | Reported |
| 2022-03-31 | $13.56M | $49.96M | $11.78M | $-50.48M | $810.00K | 27.15% | 23.57% | -62.32× | Reported |
| 2021-12-31 | $13.06M | $48.42M | $10.53M | $-47.30M | $829.00K | 26.98% | 21.75% | -57.06× | Reported |
| 2021-09-30 | $11.83M | $44.54M | $7.49M | $-44.29M | $897.00K | 26.55% | 16.82% | -49.38× | Reported |
| 2021-06-30 | $11.01M | $41.89M | $7.41M | $-38.83M | $1.79M | 26.28% | 17.69% | -21.65× | Reported |
| 2021-03-31 | $8.93M | $33.36M | $5.26M | $-38.26M | $2.50M | 26.77% | 15.76% | -15.31× | Reported |
| 2020-12-31 | $7.46M | $32.73M | $3.20M | $-32.33M | $3.18M | 22.79% | 9.77% | -10.16× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $31.74M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $35.44M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $6.05M | $32.59M | $364.00K | $-17.84M | $2.32M | 18.56% | 1.12% | -7.70× | Reported |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $6.99M | $20.00M | $366.00K | $-15.05M | $2.52M | 34.95% | 1.83% | -5.97× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Spectral AI, Inc. (MDAI) | United States | $0.052B |